Skip to main content
SpringerLink
Log in

Pamidronate after Heart Transplantation

  • Letter
  • Published:
Osteoporosis International Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Krieg MA, Seydoux C, Sandini L, Goy JJ, Berguer Gillard D, Thiebaud D, Burckhardt P. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study. Osteoporos Int 2001;12:112–6.

    Article  CAS  PubMed  Google Scholar 

  2. Body JJ. Dosing regimens and main adverse events of bisphosphonates. Semin Oncol 2001;28(4 Suppl 11):49–53.

    Article  CAS  PubMed  Google Scholar 

  3. Kraj M, Poglod R, Pawlikowski J, Maj S, Nasilowska B. Effect of pamidronate on skeletal morbidity in myelomatosis. 1. The results of the first 12 months of pamidronate therapy. Acta Pol Pharm 2000;57:113–6.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of PMR, Istanbul University, Cerrahpasa School of Medicine, Turkey

    S. Tüzün

Authors
  1. S. Tüzün
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tüzün, S. Pamidronate after Heart Transplantation. Osteoporos Int 13, 762 (2002). https://doi.org/10.1007/s001980200104

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s001980200104

Search

Navigation